Overview

• An Italian open-label study of 31 obese adults saw average monthly migraine days drop from about 20 to 11 over 12 weeks of daily liraglutide injections.
• Participants’ body weight remained stable, indicating that headache reductions were not tied to weight loss.
• Around 40% of subjects experienced mild gastrointestinal side effects such as nausea and constipation, but none discontinued treatment.
• Investigators attribute the migraine relief to reductions in cerebrospinal fluid pressure rather than metabolic changes.
• Researchers plan a larger randomized, double-blind trial to measure intracranial pressure directly and test other GLP-1 receptor agonists.